Skip to main content

5 Results for “cardioform”

Gore Marks Two-Year Primary Endpoint Follow-up Milestone in Study of GORE® CARDIOFORM Septal Occluder for Patent Foramen Ovale (PFO) Closure

Completion of follow -up paves way for REDUCE Clinical Study data submission to FDA for PFO indication

Gore Completes Patient Enrollment in U.S. Pivotal Clinical Study of GORE® CARDIOFORM ASD Occluder

New addition to GORE® CARDIOFORM Occluder family is designed to treat larger atrial septal defects by adapting to the patient’s anatomy for a permanent and safe closure

FDA Approves GORE® CARDIOFORM Septal Occluder for PFO Closure to Prevent Recurrent Ischemic Stroke

Gore REDUCE Clinical Study demonstrated 77 percent relative reduction in recurrent ischemic stroke when PFO closure was combined with antiplatelet therapy, compared to antiplatelet therapy alone

Gore Announces Positive Results from REDUCE Clinical Study for PFO Closure

Study met its primary endpoint with PFO closure in conjunction with antiplatelet therapy, reducing recurrent stroke by > 75% over antiplatelet therapy alone